loader image
Friday, September 26, 2025
76.8 F
McAllen
- Advertisement -

Gilead Partnering With 40 Companies to Scale Up Production of Promising COVID-19 Treatment

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

As the dog days of summer drag on, the heat has proven to be no match for COVID-19. Yet, the business community remains confident that something else will come to the rescue: science.

There are currently 640 clinical trials for COVID-19 therapeutics and vaccines taking place across all 50 states. Gilead’s innovative medicine, remdesivir, has been making headlines as the first antiviral treatment for COVID-19 to demonstrate patient improvement in clinical studies—enabling patients to recover more quickly, potentially freeing up provider time and hospital resources.

On Monday, the company announced it is seeking full regulatory approval for remdesivir to treat COVID-19, the final milestone needed for the medicine to be used widely with coronavirus patients. 

- Advertisement -

Because remdesivir is delivered intravenously and is complex to manufacture, Gilead is partnering with 40 companies across North America, Europe, and Asia, with a goal of meeting global demand for the medicine by October. Just last Friday, the company announced it would team up with Pfizer to produce remdesivir at Pfizer’s McPherson, Kansas facility.

The partnership illustrates the unprecedented scope of industry collaboration to combat COVID-19. Pfizer’s CEO Albert Bourla said it best: “Together, we are more powerful than alone.”

Indeed, the scope of industry collaboration also extends to R&D, with multiple studies of combination treatments underway in the hope of improving upon patient outcomes.

The National Institute of Allergy and Infectious Disease is evaluating a combination of Gilead’s remdesivir and Eli Lilly’s anti-inflammatory drug baricitinib. Studies are also underway to determine the benefits of Roche’s rheumatoid arthritis therapy tocilizumab in combination with Gilead’s remdesivir. 

- Advertisement -

Yet recently, some actors in the United States are threatening the ability of innovative companies to work together to invest in the science needed to combat COVID-19. Proposals to impose artificial price controls oroverride patent protection will hinder the research and development into life-saving treatments and cures at a time when they are desperately needed to defeat COVID-19. 

Now, more than ever, innovators need to keep their eyes on the ball to deliver solutions to COVID-19, but they can’t do it alone.

The Chamber calls on policy makers across the U.S. to reject proposals which threaten the investment in innovation that is needed to lead us beyond the coronavirus crisis once and for all.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health’s Dr. Cardenas Showcases Apprenticeship Model for Healthcare Careers

The Texas Workforce Commission hosted its 9th Annual Apprenticeship Texas Conference on September 25, 2025, at the Sheraton Dallas Hotel. Themed “Building Texas Talent – Apprenticeships of Tomorrow,” the conference featured a flagship plenary session titled “Building a Healthier Workforce.”

5 Exercises for Shoulder Health as an Older Adult

The shoulder plays a key role in movements necessary for everyday activities. Older adults can protect their shoulders by performing exercises that focus on strength and mobility. 

STHS Behavioral to Highlight Impact of Trauma on Mental Health, Oct. 2nd

Experiencing a traumatic event like a life-threatening motor vehicle accident, sexual assault or a natural disaster can alter brain structure and function, affecting areas responsible for emotional regulation, decision-making and memory.

Gene Could Impact Weight Loss Using GLP-1, Study Finds

 A study from Cleveland Clinic found variations in a certain gene, known as Neurobeachin, could play a role in whether a person loses weight using a GLP-1 medication. 
- Advertisement -
×